Changes in the cardiac metabolome caused by perhexiline treatment in a mouse model of hypertrophic cardiomyopathy

Katja Gehmlich, Michael S. Dodd, J. William Allwood, Matthew Kelly, Mohamed Bellahcene, Heena V. Lad, Alexander Stockenhuber, Charlotte Hooper, Houman Ashrafian, Charles S. Redwood, Lucie Carrier, Warwick B. Dunn

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Energy depletion has been highlighted as an important contributor to the pathology of hypertrophic cardiomyopathy (HCM), a common inherited cardiac disease. Pharmacological reversal of energy depletion appears an attractive approach and the use of perhexiline has been proposed as it is thought to shift myocardial metabolism from fatty acid to glucose utilisation, increasing ATP production and myocardial efficiency. We used the Mybpc3-targeted knock-in mouse model of HCM to investigate changes in the cardiac metabolome following perhexiline treatment. Echocardiography indicated that perhexiline induced partial improvement of some, but not all hypertrophic parameters after six weeks. Non-targeted metabolomics, applying ultra-high performance liquid chromatography-mass spectrometry, described a phenotypic modification of the cardiac metabolome with 272 unique metabolites showing a statistically significant change (p < 0.05). Changes in fatty acids and acyl carnitines indicate altered fatty acid transport into mitochondria, implying reduction in fatty acid beta-oxidation. Increased glucose utilisation is indirectly implied through changes in the glycolytic, glycerol, pentose phosphate, tricarboxylic acid and pantothenate pathways. Depleted reduced glutathione and increased production of NADPH suggest reduction in oxidative stress. These data delineate the metabolic changes occurring during improvement of the HCM phenotype and indicate the requirements for further targeted interventions.

Original languageEnglish
Pages (from-to)564-573
Number of pages10
JournalMolecular BioSystems
Volume11
Issue number2
Early online date24 Nov 2014
DOIs
Publication statusPublished - 1 Feb 2015
Externally publishedYes

Fingerprint

Perhexiline
Metabolome
Hypertrophic Cardiomyopathy
Fatty Acids
Tricarboxylic Acids
Pentoses
Glucose
Metabolomics
Carnitine
NADP
Glycerol
Glutathione
Echocardiography
Heart Diseases
Mass Spectrometry
Mitochondria
Oxidative Stress
Adenosine Triphosphate
Phosphates
High Pressure Liquid Chromatography

ASJC Scopus subject areas

  • Biotechnology
  • Molecular Biology

Cite this

Changes in the cardiac metabolome caused by perhexiline treatment in a mouse model of hypertrophic cardiomyopathy. / Gehmlich, Katja; Dodd, Michael S.; William Allwood, J.; Kelly, Matthew; Bellahcene, Mohamed; Lad, Heena V.; Stockenhuber, Alexander; Hooper, Charlotte; Ashrafian, Houman; Redwood, Charles S.; Carrier, Lucie; Dunn, Warwick B.

In: Molecular BioSystems, Vol. 11, No. 2, 01.02.2015, p. 564-573.

Research output: Contribution to journalArticle

Gehmlich, K, Dodd, MS, William Allwood, J, Kelly, M, Bellahcene, M, Lad, HV, Stockenhuber, A, Hooper, C, Ashrafian, H, Redwood, CS, Carrier, L & Dunn, WB 2015, 'Changes in the cardiac metabolome caused by perhexiline treatment in a mouse model of hypertrophic cardiomyopathy' Molecular BioSystems, vol. 11, no. 2, pp. 564-573. https://doi.org/10.1039/c4mb00594e
Gehmlich, Katja ; Dodd, Michael S. ; William Allwood, J. ; Kelly, Matthew ; Bellahcene, Mohamed ; Lad, Heena V. ; Stockenhuber, Alexander ; Hooper, Charlotte ; Ashrafian, Houman ; Redwood, Charles S. ; Carrier, Lucie ; Dunn, Warwick B. / Changes in the cardiac metabolome caused by perhexiline treatment in a mouse model of hypertrophic cardiomyopathy. In: Molecular BioSystems. 2015 ; Vol. 11, No. 2. pp. 564-573.
@article{51a4abe550f74d29b0650a1d3a361704,
title = "Changes in the cardiac metabolome caused by perhexiline treatment in a mouse model of hypertrophic cardiomyopathy",
abstract = "Energy depletion has been highlighted as an important contributor to the pathology of hypertrophic cardiomyopathy (HCM), a common inherited cardiac disease. Pharmacological reversal of energy depletion appears an attractive approach and the use of perhexiline has been proposed as it is thought to shift myocardial metabolism from fatty acid to glucose utilisation, increasing ATP production and myocardial efficiency. We used the Mybpc3-targeted knock-in mouse model of HCM to investigate changes in the cardiac metabolome following perhexiline treatment. Echocardiography indicated that perhexiline induced partial improvement of some, but not all hypertrophic parameters after six weeks. Non-targeted metabolomics, applying ultra-high performance liquid chromatography-mass spectrometry, described a phenotypic modification of the cardiac metabolome with 272 unique metabolites showing a statistically significant change (p < 0.05). Changes in fatty acids and acyl carnitines indicate altered fatty acid transport into mitochondria, implying reduction in fatty acid beta-oxidation. Increased glucose utilisation is indirectly implied through changes in the glycolytic, glycerol, pentose phosphate, tricarboxylic acid and pantothenate pathways. Depleted reduced glutathione and increased production of NADPH suggest reduction in oxidative stress. These data delineate the metabolic changes occurring during improvement of the HCM phenotype and indicate the requirements for further targeted interventions.",
author = "Katja Gehmlich and Dodd, {Michael S.} and {William Allwood}, J. and Matthew Kelly and Mohamed Bellahcene and Lad, {Heena V.} and Alexander Stockenhuber and Charlotte Hooper and Houman Ashrafian and Redwood, {Charles S.} and Lucie Carrier and Dunn, {Warwick B.}",
year = "2015",
month = "2",
day = "1",
doi = "10.1039/c4mb00594e",
language = "English",
volume = "11",
pages = "564--573",
journal = "Molecular BioSystems",
issn = "1742-206X",
publisher = "Royal Society of Chemistry",
number = "2",

}

TY - JOUR

T1 - Changes in the cardiac metabolome caused by perhexiline treatment in a mouse model of hypertrophic cardiomyopathy

AU - Gehmlich, Katja

AU - Dodd, Michael S.

AU - William Allwood, J.

AU - Kelly, Matthew

AU - Bellahcene, Mohamed

AU - Lad, Heena V.

AU - Stockenhuber, Alexander

AU - Hooper, Charlotte

AU - Ashrafian, Houman

AU - Redwood, Charles S.

AU - Carrier, Lucie

AU - Dunn, Warwick B.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Energy depletion has been highlighted as an important contributor to the pathology of hypertrophic cardiomyopathy (HCM), a common inherited cardiac disease. Pharmacological reversal of energy depletion appears an attractive approach and the use of perhexiline has been proposed as it is thought to shift myocardial metabolism from fatty acid to glucose utilisation, increasing ATP production and myocardial efficiency. We used the Mybpc3-targeted knock-in mouse model of HCM to investigate changes in the cardiac metabolome following perhexiline treatment. Echocardiography indicated that perhexiline induced partial improvement of some, but not all hypertrophic parameters after six weeks. Non-targeted metabolomics, applying ultra-high performance liquid chromatography-mass spectrometry, described a phenotypic modification of the cardiac metabolome with 272 unique metabolites showing a statistically significant change (p < 0.05). Changes in fatty acids and acyl carnitines indicate altered fatty acid transport into mitochondria, implying reduction in fatty acid beta-oxidation. Increased glucose utilisation is indirectly implied through changes in the glycolytic, glycerol, pentose phosphate, tricarboxylic acid and pantothenate pathways. Depleted reduced glutathione and increased production of NADPH suggest reduction in oxidative stress. These data delineate the metabolic changes occurring during improvement of the HCM phenotype and indicate the requirements for further targeted interventions.

AB - Energy depletion has been highlighted as an important contributor to the pathology of hypertrophic cardiomyopathy (HCM), a common inherited cardiac disease. Pharmacological reversal of energy depletion appears an attractive approach and the use of perhexiline has been proposed as it is thought to shift myocardial metabolism from fatty acid to glucose utilisation, increasing ATP production and myocardial efficiency. We used the Mybpc3-targeted knock-in mouse model of HCM to investigate changes in the cardiac metabolome following perhexiline treatment. Echocardiography indicated that perhexiline induced partial improvement of some, but not all hypertrophic parameters after six weeks. Non-targeted metabolomics, applying ultra-high performance liquid chromatography-mass spectrometry, described a phenotypic modification of the cardiac metabolome with 272 unique metabolites showing a statistically significant change (p < 0.05). Changes in fatty acids and acyl carnitines indicate altered fatty acid transport into mitochondria, implying reduction in fatty acid beta-oxidation. Increased glucose utilisation is indirectly implied through changes in the glycolytic, glycerol, pentose phosphate, tricarboxylic acid and pantothenate pathways. Depleted reduced glutathione and increased production of NADPH suggest reduction in oxidative stress. These data delineate the metabolic changes occurring during improvement of the HCM phenotype and indicate the requirements for further targeted interventions.

UR - http://www.scopus.com/inward/record.url?scp=84921503968&partnerID=8YFLogxK

U2 - 10.1039/c4mb00594e

DO - 10.1039/c4mb00594e

M3 - Article

VL - 11

SP - 564

EP - 573

JO - Molecular BioSystems

JF - Molecular BioSystems

SN - 1742-206X

IS - 2

ER -